Ling Liu
Andy Ho
July 3, 2024
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the appointment of Ms Ling Liu as the Chief Region Leader of Philips Greater China, effective immediately. Ms Liu is now a member of Philips’ Executive Committee, reporting to Philips CEO Roy Jakobs. She succeeds Andy Ho, who has decided to retire after a long and successful career. Ms Liu and Mr Ho continue to work together to ensure a smooth handover.
“Ling is a talented, trusted leader and I am delighted that she will join Philips’ Executive Committee as the Chief Region Leader of Philips Greater China,” said Roy Jakobs, CEO of Royal Philips. “She is a proven executive who brings a wealth of international experience and deep HealthTech expertise in China. I would also like to express my deep gratitude to Andy for his exceptional leadership in delivering on our commitment to supporting China’s national health strategy and becoming a trusted partner for professional customers as well as individual consumers. At the same time as driving sustained financial and operational performance over the last nine years.”
Ms Liu joined Philips in 1998 and has held multiple roles across the business, living and working in Greater China, the Netherlands and North America. Most recently, she was Chief Commercial Officer in Greater China, following her role as Head of Finance for Philips in North America. She has a track record of driving execution and boosting performance, developing teams and delivering outstanding value to customers and partners. She is passionate about delivering quality care and contributing to sustainable healthcare in China.
Ms Liu holds a master of finance and control from Maastricht University, a master’s degree in management engineering from Shanghai University, and a bachelor’s degree in physics from Zhejiang University.
2023 marked the 100th anniversary of Philips in China, an achievement that stands as a testament to Philips’ commitment and dedication to improving people’s lives through meaningful innovation and fostering strong partnerships in China. With sustained growth and being Philips’ second largest market, it has been one of the major growth engines for the company. Philips China is focused on supporting China’s national health strategy, supplying hospitals with solutions for their clinical and research needs, and empowering consumers to manage their health and well-being. With the aim of better serving the Chinese market, Philips is committed to its ‘In China, For China’ strategy, which focuses on local innovation, manufacturing, services and partnership.
Additional information on Philips’ Executive Committee can be found here.
For further information, please contact:
Ben Zwirs
Philips External Relations
Tel.: +31 6 1521 3446
E-mail: ben.zwirs@philips.com
Dorin Danu
Philips Investor Relations
Tel.: +31 20 59 77055
E-mail: dorin.danu@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2023 sales of EUR 18.2 billion and employs approximately 69,100 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Forward-looking statements
This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.
Attachments
